Synchrony Financial has seen its share price rise by 33% over the last month, influenced by several key developments. The company announced a significant new partnership with Texas A&M University Veterinary Medical Teaching Hospital, enhancing its CareCredit services in veterinary financing, and launched a private label credit card with Belle Tire, broadening its reach in auto-related financing. Additionally, Synchrony’s decisions to increase dividends and authorize a new $2.5 billion share buyback program likely provided further confidence to investors. These positive moves contrast with the company’s mixed earnings report but align well with a broadly rising market.
Synchrony Financial has 1 weakness we think you should know about.
NYSE:SYF Earnings Per Share Growth as at May 2025
The end of cancer? These 24 emerging AI stocks are developing tech that will allow early…
